Tag: Anti inflammatory Biologics Market 2025

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Anti-Inflammatory Biologics Market Size And Revenue Outlook Through 2030

The anti-inflammatory biologics market size has demonstrated significant growth over recent years. It is projected to increase from $118.02 billion in 2025 to $128.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical expansion can be attributed to various factors, including the increasing prevalence of conditions such as rheumatoid arthritis and psoriasis, the strengthening of hospital and clinic infrastructure, and greater investment in immunology research. Additionally, the initial limited availability of biologics and a previous reliance on traditional anti-inflammatory drugs also contributed to this growth.

The anti-inflammatory biologics market size is projected to experience substantial growth in the upcoming years. It is expected to expand to $180.93 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. This anticipated growth can be attributed to several factors, including the advancement of next-generation cytokine inhibitors, the broadening of home care and self-administration choices, an increase in regulatory approvals coupled with swifter clinical trial processes, escalating investment in precision medicine and biologics research and development, and the expansion of partnerships between pharmaceutical and biotechnology enterprises. Significant trends for the forecast period comprise the increasing utilization of targeted biologics for persistent inflammatory conditions, the wider adoption of subcutaneous and injectable drug delivery methods, a surge in clinical trials and research dedicated to innovative anti-inflammatory biologics, an intensified focus on customized treatment approaches, and enhanced awareness and availability of biologics in developing markets.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Anti-Inflammatory Biologics Market Growth Backed By Core Demand Fundamentals

The increasing incidence of arthritis is projected to drive the expansion of the anti-inflammatory biologics market in the foreseeable future. Arthritis is defined as the inflammation or swelling in one or more joints, leading to pain, stiffness, and reduced movement, often worsening with advancing age. The heightened prevalence of arthritis primarily stems from rising obesity rates, as excess body weight places additional stress on joints, which in turn causes inflammation and joint degeneration. Anti-inflammatory biologics prove beneficial for arthritis by targeting specific components of the immune system to decrease inflammation, slow down joint damage, relieve symptoms, and enhance physical function and quality of life for individuals with moderate to severe arthritis. For example, in January 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, 18.4% of people aged 16 and over indicated they had a long-term MSK condition, an increase from 17.6% in 2022. Thus, the growing prevalence of arthritis is fueling the growth of the anti-inflammatory biologics market.

Anti-Inflammatory Biologics Market Segmentation And Category Overview

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics

Anti-Inflammatory Biologics Market Growth Trends Reshaping The Competitive Landscape

Leading firms within the anti-inflammatory biologics sector are concentrating on creating novel treatments, including interleukin-6 (IL-6) receptor antagonists, to address chronic inflammatory conditions more precisely and with fewer adverse reactions. Interleukin-6 (IL-6) receptor antagonists are a class of biologic medications designed to obstruct the IL-6 receptor, thereby diminishing inflammation and immune activity in illnesses like rheumatoid arthritis. For example, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained clearance from the US Food and Drug Administration (FDA) for Kevzara. This marks Kevzara as the initial and sole biologic therapy for individuals suffering from polymyalgia rheumatica (PMR) who exhibit an insufficient response to corticosteroids. Kevzara functions as a fully human monoclonal antibody, inhibiting the IL-6 receptor to aid in lessening the inflammation associated with PMR, a condition predominantly affecting older adults with symptoms of muscle pain and stiffness. In contrast to conventional steroids, which pose long-term risks like osteoporosis and diabetes, Kevzara offers a more focused, steroid-reducing method, promoting better patient results and heightened long-term safety.

Anti-Inflammatory Biologics Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A

View The Full Anti-Inflammatory Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Anti-Inflammatory Biologics Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Anti-Inflammatory Biologics Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for anti-inflammatory biologics has experienced substantial expansion in recent years. Projections indicate it will increase from $118.02 billion in 2025 to $128.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth has been driven by factors such as the constrained availability of biologics, dependence on conventional anti-inflammatory medications, a rising incidence of rheumatoid arthritis and psoriasis, the development of hospital and clinic facilities, and growing financial commitments to immunology research.

The anti-inflammatory biologics market is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $180.93 billion, driven by a compound annual growth rate (CAGR) of 8.9%. This forecasted growth is fueled by the emergence of next-generation cytokine inhibitors, broader availability of home care and self-administration options, an uptick in regulatory approvals alongside expedited clinical trial timelines, heightened investment in precision medicine and biologics research, and expanding collaborations between pharmaceutical and biotechnology firms. Key trends shaping this period include a growing preference for targeted biologics addressing chronic inflammatory conditions, advancements in subcutaneous and injectable drug delivery methods, an increase in clinical trials and research into novel anti-inflammatory biologics, a stronger emphasis on tailored treatment approaches, and greater awareness and accessibility of biologics within emerging markets.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Anti-Inflammatory Biologics Market Demand Drivers: What Is Fueling Industry Growth?

The upward trend in arthritis cases is anticipated to fuel the expansion of the anti-inflammatory biologics market in the coming period. Arthritis is characterized by joint inflammation or swelling, which results in pain, stiffness, and diminished mobility, and these symptoms tend to intensify with advancing age. This increase in arthritis prevalence is largely attributable to climbing obesity rates, as surplus body weight imposes increased pressure on joints, thereby triggering inflammation and joint deterioration. Anti-inflammatory biologics prove beneficial for managing arthritis by zeroing in on particular immune system elements to curb inflammation, decelerate joint deterioration, alleviate symptoms, and enhance both physical function and overall quality of life for individuals suffering from moderate to severe arthritis. As an example, data from the Office for Health Improvement and Disparities, a UK government body, indicates that in January 2024, 18.4% of people aged 16 and over in 2023 reported a long-term musculoskeletal condition, an increase from 17.6% in 2022. Consequently, the growing occurrence of arthritis is propelling the advancement of the anti-inflammatory biologics market.

Anti-Inflammatory Biologics Market Segment Analysis And Revenue Opportunities

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics

Anti-Inflammatory Biologics Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading firms in the anti-inflammatory biologics sector are concentrating on creating innovative products, including interleukin-6 (IL-6) receptor antagonists, to treat chronic inflammatory diseases with enhanced precision and minimized adverse effects. These biologic drugs work by blocking the IL-6 receptor, thereby dampening inflammation and immune activity in disorders like rheumatoid arthritis. A notable example occurred in February 2023, when Regeneron Pharmaceuticals Inc., a biotechnology company based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for Kevzara. This approval marked it as the first and only biologic therapy indicated for patients with polymyalgia rheumatica (PMR) who have an inadequate response to corticosteroids. Kevzara, a fully human monoclonal antibody, functions by inhibiting the IL-6 receptor, which alleviates inflammation associated with PMR—a condition characterized by muscle pain and stiffness, typically affecting older individuals. In contrast to conventional steroids, which pose risks like osteoporosis and diabetes when used over extended periods, Kevzara offers a more targeted, steroid-sparing therapeutic option that promotes better patient outcomes and improved long-term safety.

Anti-Inflammatory Biologics Market Leading Players Shaping Industry Direction

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A

Access The Complete Anti-Inflammatory Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Anti-Inflammatory Biologics Market Regional Analysis And Leading Geography

North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Anti-Inflammatory Biologics Market In 2026, And How Will Its Value Evolve By 2030?

The anti-inflammatory biologics market size has shown robust growth in recent years. It is anticipated to expand from $118.02 billion in 2025 to $128.84 billion in 2026, at a compound annual growth rate (CAGR) of 9.2%. This historical growth can be attributed to factors such as the limited availability of biologics, reliance on traditional anti-inflammatory drugs, the increasing prevalence of rheumatoid arthritis and psoriasis, the development of hospital and clinic infrastructure, and rising investment in immunology research.

The anti-inflammatory biologics market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $180.93 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. Several factors are contributing to this projected growth, including the advancement of next-generation cytokine inhibitors, the broadening availability of home care and self-administration methods, a rise in regulatory approvals alongside accelerated clinical trial procedures, increased funding directed towards precision medicine and biologics research and development, and the burgeoning collaborations between pharmaceutical and biotechnology firms. Key trends anticipated during this period encompass the increasing acceptance of targeted biologics for long-term inflammatory conditions, the broader application of subcutaneous and injectable drug delivery systems, a surge in clinical trials and investigations into new anti-inflammatory biologics, a greater emphasis on customized treatment strategies, and enhanced awareness and availability of biologics in emerging markets.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

Which Factors Are Influencing The Growth Of The Anti-Inflammatory Biologics Market?

The increasing incidence of arthritis is projected to drive the expansion of the anti-inflammatory biologics market in the future. Arthritis is characterized by the inflammation or swelling of one or more joints, leading to discomfort, rigidity, and impaired mobility, frequently deteriorating as individuals age. This growing occurrence of arthritis largely stems from escalating obesity rates, given that surplus body weight exerts extra pressure on joints, contributing to inflammation and joint breakdown. For individuals suffering from moderate to severe arthritis, anti-inflammatory biologics prove beneficial by targeting particular elements of the immune system, thereby lessening inflammation, decelerating joint deterioration, alleviating symptoms, and enhancing physical capabilities and overall well-being. As an illustration, in January 2024, data from the Office for Health Improvement and Disparities, a UK government department, indicated that in 2023, 18.4% of individuals aged 16 and above reported experiencing a long-term MSK condition, which was an increase from 17.6% recorded in 2022. Consequently, the expanding occurrence of arthritis is stimulating the development of the anti-inflammatory biologics market.

How Is The Anti-Inflammatory Biologics Market Categorized Across Its Segment Groups?

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics

Which Trends Are Shaping The Anti-Inflammatory Biologics Market?

Major companies in the anti-inflammatory biologics market are concentrating on developing innovative solutions, such as interleukin-6 (IL-6) receptor antagonists, to target chronic inflammatory diseases with increased specificity and fewer side effects. Interleukin-6 (IL-6) receptor antagonists are biologic drugs that work by blocking the IL-6 receptor, thereby reducing inflammation and immune response in conditions like rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained approval from the US Food and Drug Administration (FDA) for Kevzara. This approval designated Kevzara as the first and only biologic treatment for patients with polymyalgia rheumatica (PMR) who do not adequately respond to corticosteroids. Kevzara is a fully human monoclonal antibody designed to block the IL-6 receptor, which helps mitigate inflammation linked to PMR, a condition primarily affecting older adults and causing muscle pain and stiffness. Unlike traditional steroids, which carry risks such as osteoporosis and diabetes with prolonged administration, Kevzara offers a more targeted, steroid-sparing approach, supporting enhanced patient outcomes and improved long-term safety.

Which Firms Are Influencing Competition In The Anti-Inflammatory Biologics Market?

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A

Get The Full Anti-Inflammatory Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

Where Is The Anti-Inflammatory Biologics Market Primarily Concentrated By Region?

North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Anti-Inflammatory Biologics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2026, By The Business Research Company

Anti Inflammatory Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Non Steroidal Anti Inflammatory Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Anti-Inflammatory Biologics Market Over The 2026–2030 Period?

The anti-inflammatory biologics market has shown substantial expansion in recent years. It is anticipated to grow from $118.02 billion in 2025 to $128.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The past growth of this market is attributable to several factors, including the constrained availability of biologics, a reliance on traditional anti-inflammatory drugs, the increasing prevalence of rheumatoid arthritis and psoriasis, the development of hospital and clinic infrastructure, and rising investment in immunology research.

The anti-inflammatory biologics market size is poised for robust expansion over the next few years. It is forecast to swell to $180.93 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.9%. This projected growth during the forecast period is attributable to several factors, including the creation of next-generation cytokine inhibitors, an increase in home care and self-administration choices, a rise in regulatory approvals and more rapid clinical trial processes, increased investment in precision medicine and biologics research and development, and the formation of more partnerships between pharmaceutical and biotechnology companies. Significant trends anticipated during the forecast period involve the increasing uptake of targeted biologics for chronic inflammatory diseases, the broadening of subcutaneous and injectable drug delivery methods, an escalation in clinical trials and research for innovative anti-inflammatory biologics, a heightened emphasis on personalized treatment regimens, and greater awareness and access to biologics within emerging markets.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

Which Major Factors Are Driving The Expansion Of The Anti-Inflammatory Biologics Market?

The escalating prevalence of arthritis is anticipated to stimulate the expansion of the anti-inflammatory biologics market in the foreseeable future. Arthritis, characterized by inflammation or swelling in one or more joints, leads to discomfort, stiffness, and diminished mobility, often worsening with advancing age. This uptick in arthritis cases is predominantly attributed to rising obesity levels, as excess body weight places additional strain on joints, contributing to inflammation and joint deterioration. Anti-inflammatory biologics effectively manage arthritis by targeting specific immune system components to mitigate inflammation, slow the progression of joint damage, alleviate symptoms, and enhance both physical function and overall quality of life for individuals with moderate to severe forms of the condition. As an illustration, in January 2024, data from the UK’s Office for Health Improvement and Disparities revealed that in 2023, 18.4% of people aged 16 and over reported having a long-term musculoskeletal (MSK) condition, marking an increase from 17.6% in 2022. Consequently, the increasing prevalence of arthritis acts as a significant catalyst for the growth of the anti-inflammatory biologics market.

How Is The Anti-Inflammatory Biologics Market Segmented Across Key Categories?

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics

Which Upcoming Trends Are Expected To Influence The Anti-Inflammatory Biologics Market?

Leading firms within the anti-inflammatory biologics market are concentrating on creating advanced treatments, including interleukin-6 (IL-6) receptor antagonists, designed to address chronic inflammatory conditions with enhanced precision and fewer adverse effects. These interleukin-6 (IL-6) receptor antagonists are biological medications that obstruct the IL-6 receptor, thereby diminishing inflammation and immune reactions in diseases like rheumatoid arthritis. As an illustration, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology enterprise, secured authorization from the US Food and Drug Administration (FDA) for Kevzara. This drug represents the initial and sole biologic therapy specifically for individuals suffering from polymyalgia rheumatica (PMR) who exhibit insufficient response to corticosteroids. Kevzara functions as a fully human monoclonal antibody that impedes the IL-6 receptor, assisting in alleviating the inflammation associated with PMR, a disorder primarily affecting older adults and characterized by muscle pain and stiffness. In contrast to conventional steroids, which can pose risks like osteoporosis and diabetes during extended administration, Kevzara offers a more precise, steroid-reducing method, leading to better patient results and heightened long-term safety.

Who Are The Dominant Players Shaping The Anti-Inflammatory Biologics Market Landscape?

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A

Read the full anti-inflammatory biologics market report here:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

Which Region Currently Holds The Largest Share Of The Anti-Inflammatory Biologics Market?

North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anti-Inflammatory Biologics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp

Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2026, By The Business Research Company

Anti Inflammatory Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Non Steroidal Anti Inflammatory Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the anti-inflammatory biologics market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Anti-Inflammatory Biologics Market in 2026, and what figure is it projected to hit by 2030?

The anti-inflammatory biologics market has seen significant expansion in recent years. This market is set to expand from $118.02 billion in 2025 to $128.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. The historical development of this market can be ascribed to a limited supply of biologics, reliance on traditional anti-inflammatory drugs, increasing prevalence of rheumatoid arthritis and psoriasis, growth of hospital and clinic infrastructure, and rising investment in immunology research.

The anti-inflammatory biologics market size is anticipated to expand significantly over the coming years, projected to reach $180.93 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. This growth during the forecast period is attributable to the advancement of next-generation cytokine inhibitors, the increased availability of home care and self-administration alternatives, a surge in regulatory approvals and accelerated clinical trial procedures, escalating investment in precision medicine and biologics research and development, and the proliferation of partnerships between pharmaceutical and biotech enterprises. Significant trends for the forecast period include the growing acceptance of targeted biologics for chronic inflammatory conditions, the broader adoption of subcutaneous and injectable drug delivery systems, an increase in clinical trials and research for innovative anti-inflammatory biologics, a heightened focus on personalized treatment strategies, and improved awareness and access to biologics in developing markets.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

Which Drivers Are Affecting Market Participation In The Anti-Inflammatory Biologics Market?

The increasing occurrence of arthritis is anticipated to fuel the expansion of the anti-inflammatory biologics market in the foreseeable future. Arthritis is defined as the inflammation or swelling affecting one or more joints, leading to discomfort, rigidity, and restricted mobility, frequently intensifying with advancing age. This escalating prevalence of arthritis largely stems from growing obesity levels, where surplus body weight exerts extra pressure on joints, contributing to inflammation and the deterioration of joint tissue. Anti-inflammatory biologics offer benefits for arthritis patients by targeting precise elements of the immune system, thereby diminishing inflammation, decelerating joint deterioration, alleviating symptoms, and enhancing both physical capabilities and overall life quality for individuals suffering from moderate to severe forms of the condition. As an illustration, data from January 2024, provided by the Office for Health Improvement and Disparities, a UK government body, indicated that in 2023, 18.4% of individuals aged 16 and above reported experiencing a long-term MSK condition, which was an increase from 17.6% in 2022. Consequently, the increasing incidence of arthritis is a key factor propelling the expansion of the anti-inflammatory biologics market.

What Segment Categories Are Covered In The Anti-Inflammatory Biologics Market?

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics

Which Trends Are Shaping Activity Within The Anti-Inflammatory Biologics Market?

Leading companies in the anti-inflammatory biologics market are concentrating on creating novel solutions, such as interleukin-6 (IL-6) receptor antagonists, to address chronic inflammatory diseases with increased precision and fewer adverse effects. Interleukin-6 (IL-6) receptor antagonists are a class of biologic medicines that impede the IL-6 receptor to lessen inflammation and immune responses in conditions like rheumatoid arthritis. For example, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology firm, obtained approval from the US Food and Drug Administration (FDA) for Kevzara, marking it as the initial and sole biologic treatment specifically indicated for individuals with polymyalgia rheumatica (PMR) who exhibit an inadequate response to corticosteroids. Kevzara functions as a fully human monoclonal antibody that obstructs the IL-6 receptor, thereby helping to diminish inflammation associated with PMR, a condition characterized by muscle pain and stiffness, predominantly affecting older adults. In contrast to conventional steroids, which present risks such as osteoporosis and diabetes with extended usage, Kevzara offers a more directed, steroid-sparing strategy that supports better patient results and enhanced long-term safety.

Which Key Market Players Are Investing In Expansion And Innovation Within The Anti-Inflammatory Biologics Market?

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

Which Regions Are Poised For Strategic Growth In The Anti-Inflammatory Biologics Market?

North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anti-Inflammatory Biologics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp

Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2026, By The Business Research Company

Anti Inflammatory Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Non Steroidal Anti Inflammatory Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Anti-Inflammatory Biologics Industry By 2029?

The market size for anti-inflammatory biologics has been witnessing substantial growth in the recent past. It is projected to expand from $108.11 billion in 2024 to $118.02 billion in 2025, at a compound annual growth rate (CAGR) of 9.2%. Factors such as increasing cases of arthritis, heightened awareness of autoimmune diseases, the introduction of new biologic treatments, enhanced healthcare infrastructure, and an uptick in regulatory approvals contribute to the growth observed during the historical period.

In the coming few years, the anti-inflammatory biologics market size is anticipated to experience robust growth. The market is projected to reach $166.28 billion by 2029, with a compound annual growth rate (CAGR) of 9.0%. This growth over the forecast period could be credited to factors like the growing adoption of biologics, a surge in demand for targeted therapies, an uptick in patient preference for lasting remission, and expanded uses of biomarkers for tracking diseases, along with an increased demand for personalized medicine. The forecast period is also expected to witness trends such as progression in the development of biologic drugs, the creation of oral biologics to combat inflammation, advancement in drug delivery systems driven by technology, developments in the field of biosimilars, and enhancements in diagnostic tools.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

Which Factors Are Steering Growth In The Anti-Inflammatory Biologics Market?

The growth of the anti-inflammatory biologics market is anticipated to be driven by the increasing incidence of arthritis. This condition, marked by inflammation or swelling of one or more joints leading to pain, stiffness, and limited movement, often diminishes with age. The primary contributor to the growing incidence of arthritis is the rising rate of obesity, as excess body weight exerts more pressure on joints, resulting in inflammation and joint degradation. Anti-inflammatory biologics are beneficial in arthritis treatment as they target precise components of the immune system to decrease inflammation, mitigate joint damage, alleviate symptoms, and enhance physical functionality and life quality for individuals with moderate to severe arthritis. For example, data from the Office for Health Improvement and Disparities, a UK government body, indicated that in 2022, 17.6% of individuals aged 16 and older were suffering from a chronic MSK disorder such as arthritis or persistent back or joint issues, a rise from the 17.0% recorded in 2021. Consequently, the growing prevalence of arthritis is propelling the expansion of the anti-inflammatory biologics market.

Which Segment Accounts For The Largest Share In The Anti-Inflammatory Biologics Market?

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Phosphodiesterase-4 Inhibitors, Sphingosine 1-Phosphate Receptor Modulators, Anti-IgE And Other Biologics

Which Long-Term Trends Will Play A Crucial Role In The Anti-Inflammatory Biologics Market?

Leading firms in the anti-inflammatory biologics market are prioritizing the creation of novel solutions like interleukin-6 (IL-6) receptor antagonists. These offer a more specific approach and fewer side effects for chronic inflammatory illnesses. Biologic drugs, like these IL-6 receptor antagonists, function by inhibiting the IL-6 receptor and thus mitigating inflammation and the immune response in conditions like rheumatoid arthritis. In February 2023, for instance, the US-based biotechnology firm, Regeneron Pharmaceuticals Inc., received US Food and Drug Administration (FDA) approval for Kevzara. This is the first and only biologic treatment for polymyalgia rheumatica (PMR) patients who don’t respond well to corticosteroids. Kevzara, a completely human monoclonal antibody, blocks the IL-6 receptor and combats PMR-associated inflammation. PMR is a disease leading to muscular pain and rigidity, most often in the elderly. Unlike common steroids that may lead to osteoporosis and diabetes with long-term use, Kevzara offers a more direct, steroid-conserving tactic which can result in better patient results and superior long-term safety.

Who Are The Dominant Players In The Anti-Inflammatory Biologics Market Today?

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, Hansa Biopharma AB.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

What Regional Factors Are Accelerating Growth In The Anti-Inflammatory Biologics Market?

North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp

Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2025, By The Business Research Company

Rheumatology Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Wound Care Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wound-care-biologics-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model